Pharmaceutical Technology3m
FDA clamps partial hold on Phase III trial of BioNTech & OncoC4’s NSCLC therapy
A partial hold was placed on the trial after results showed variance between squamous and non-squamous NSCLC patient ...
Pharmaceutical Technology1h
FibroBiologics and Charles River link for chronic disease therapies manufacture
FibroBiologics has entered a master services agreement with Charles River Laboratories to develop and manufacture cell-based ...
Pharmaceutical Technology4h
FDA approves Astellas’ VYLOY for gastric cancer treatment
Astellas Pharma has received approval from the FDA for VYLOY in conjunction with chemotherapy, for the treatment of advanced ...
Pharmaceutical Technology10h
AAO 2024: EyePoint’s EYP-1901 proves non-inferiority to aflibercept in DAVIO 2
While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.